The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
about
PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242Microenvironment drug resistance in multiple myeloma: emerging new players.Mechanisms of Resistance in Multiple Myeloma.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Emerging immune targets for the treatment of multiple myeloma.Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds.
P2860
The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The insulin-like growth factor ...... stic and therapeutic potential
@ast
The insulin-like growth factor ...... stic and therapeutic potential
@en
The insulin-like growth factor ...... stic and therapeutic potential
@nl
type
label
The insulin-like growth factor ...... stic and therapeutic potential
@ast
The insulin-like growth factor ...... stic and therapeutic potential
@en
The insulin-like growth factor ...... stic and therapeutic potential
@nl
prefLabel
The insulin-like growth factor ...... stic and therapeutic potential
@ast
The insulin-like growth factor ...... stic and therapeutic potential
@en
The insulin-like growth factor ...... stic and therapeutic potential
@nl
P2093
P2860
P50
P921
P3181
P356
P1433
P1476
The insulin-like growth factor ...... stic and therapeutic potential
@en
P2093
Cheryl A Conover
Els Van Valckenborgh
Karin Vanderkerken
Liesbeth Bieghs
P2860
P304
48732-48752
P3181
P356
10.18632/ONCOTARGET.8982
P407
P5008
P577
2016-07-26T00:00:00Z